Dupilumab for Moderate-to-Severe Asthma
Dupilumab is indicated as add-on maintenance therapy for patients aged ≥6 years with moderate-to-severe asthma with a type 2 inflammatory phenotype (elevated blood eosinophils ≥150 cells/µL or FeNO ≥20 ppb) who remain uncontrolled on medium-to-high dose inhaled corticosteroids plus long-acting beta-agonists.
Indications and Patient Selection
Dupilumab should be considered for:
- Adults and adolescents ≥12 years: Moderate-to-severe asthma inadequately controlled on medium-to-high dose ICS plus LABA 1
- Children 6-11 years: Moderate-to-severe asthma with type 2 inflammation 1
- Oral corticosteroid-dependent asthma: Patients requiring step 5-6 care who need chronic systemic steroids 1
The strongest evidence supports use in patients with type 2 inflammatory biomarkers—specifically blood eosinophils ≥300 cells/µL or FeNO ≥25 ppb, where exacerbation reductions reach 65-81% 2, 3. However, efficacy is demonstrated even in patients with eosinophils <300 cells/µL, with 60-68% exacerbation reduction 3.
Key Clinical Context
While older asthma guidelines 4 recommend omalizumab for step 5-6 care in allergic asthma, these predate dupilumab's approval. Dupilumab represents a more broadly applicable biologic option as it targets IL-4/IL-13 signaling regardless of IgE levels, making it suitable for both allergic and non-allergic type 2 asthma 5.
Dosing Regimens
Adults and Adolescents ≥12 Years 1
Standard dosing:
- Initial: 400 mg (two 200 mg injections) OR 600 mg (two 300 mg injections)
- Maintenance: 200 mg every 2 weeks OR 300 mg every 2 weeks
For specific populations requiring 300 mg Q2W:
- Oral corticosteroid-dependent asthma
- Co-morbid moderate-to-severe atopic dermatitis
- Adults with co-morbid chronic rhinosinusitis with nasal polyps
Children 6-11 Years 1
| Body Weight | Dosing |
|---|---|
| 15 to <30 kg | 300 mg every 4 weeks |
| ≥30 kg | 200 mg every 2 weeks |
Exception: Children with co-morbid moderate-to-severe atopic dermatitis require an initial loading dose per atopic dermatitis guidelines 1.
Clinical Efficacy
The pivotal QUEST trial 2 demonstrated in 1,902 patients:
- 47.7% reduction in severe exacerbations (annualized rate 0.46 vs 0.87 with placebo, p<0.001)
- 0.14 L improvement in pre-bronchodilator FEV₁ at week 12 (p<0.001)
- Sustained improvements in ACQ-5 and asthma quality of life scores
Long-term data from the TRAVERSE extension study 6 followed patients up to 148 weeks, confirming:
- Sustained low exacerbation rates (0.277-0.327 annualized)
- Maintained FEV₁ improvements (0.22-0.33 L from baseline)
- Progressive reduction in type 2 biomarkers over time
A critical post-hoc analysis 7 showed that dupilumab plus medium-dose ICS outperformed placebo plus high-dose ICS, with 70% exacerbation reduction (p<0.0001), challenging the traditional approach of ICS dose escalation before adding biologics.
Monitoring Guidelines
Baseline Assessment
- Blood eosinophil count and FeNO to confirm type 2 phenotype
- Baseline FEV₁ and asthma control questionnaires (ACQ-5)
- Screen for parasitic infections (dupilumab may mask eosinophilic response)
Follow-up Monitoring
Eosinophilia surveillance is critical:
- Monitor blood eosinophils at weeks 4,12, and then every 3-6 months 8
- Transient eosinophilia (>1,500 cells/µL) occurs in ~4% of patients 2 and typically resolves spontaneously
- Hypereosinophilia (>5,000 cells/µL) is rare but requires evaluation for eosinophil-related organ involvement 8
Clinical response assessment:
- Evaluate exacerbation frequency, FEV₁, and ACQ-5 scores at 12-16 weeks
- Assess for oral corticosteroid dose reduction in OCS-dependent patients
- Monitor for injection site reactions (13-26% incidence) and upper respiratory infections 3
Common Pitfall
Do not discontinue dupilumab solely for asymptomatic eosinophilia <5,000 cells/µL without evidence of end-organ involvement. Most cases resolve without intervention 8.
Safety Profile
Dupilumab demonstrates excellent long-term safety over 148 weeks 6:
- Most common adverse events: nasopharyngitis (17.5-25.9%), injection site reactions (2.2-23.4%)
- Serious asthma exacerbations: 0.5-3.6%
- No increased infection risk compared to placebo
- Anaphylaxis is rare; first two injections should be administered in a healthcare setting 1
Ocular adverse events (conjunctivitis, dry eyes) occur in 6-15% in trials but up to 26% in real-world data 9. Only 4.2% discontinue due to ocular complications 9. Manage with preservative-free lubricants and ophthalmology referral if refractory.
Treatment Algorithm
- Confirm uncontrolled asthma on medium-to-high dose ICS + LABA (≥2 exacerbations/year or ACQ-5 ≥1.5)
- Document type 2 inflammation: Blood eosinophils ≥150 cells/µL OR FeNO ≥20 ppb
- Initiate dupilumab with appropriate weight/age-based dosing
- Assess response at 12-16 weeks: Expect ≥50% exacerbation reduction, FEV₁ improvement ≥0.1 L, ACQ-5 improvement ≥0.5
- Continue long-term if responding; data support use up to 148 weeks with sustained benefit
For oral corticosteroid-dependent patients: Use 300 mg Q2W dosing and attempt OCS taper after 12 weeks of dupilumab, reducing by 5-10 mg prednisone equivalent every 2-4 weeks while monitoring asthma control.